+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Velaglucerase Alfa"

From
From
From
Gaucher Disease Type 1 Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Gaucher Disease Type 1 Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Velaglucerase alfa is a recombinant form of glucocerebrosidase, an enzyme used to treat Gaucher disease, a rare genetic disorder that affects the metabolism of lipids. It is a type of endocrine and metabolic disorder drug, and is administered intravenously. Velaglucerase alfa works by replacing the missing enzyme in the body, allowing it to break down fatty substances that accumulate in the organs and tissues of patients with Gaucher disease. Velaglucerase alfa is approved by the US Food and Drug Administration (FDA) and is available in many countries around the world. It is marketed by several companies, including Shire, Pfizer, and Sanofi. It is also available in generic forms from other manufacturers. Show Less Read more